202 related articles for article (PubMed ID: 22302271)
1. Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei.
Choudry HA; Mavanur A; O'Malley ME; Zeh HJ; Guo Z; Bartlett DL
Ann Surg Oncol; 2012 May; 19(5):1402-9. PubMed ID: 22302271
[TBL] [Abstract][Full Text] [Related]
2. Mitogen-activated protein kinase inhibition reduces mucin 2 production and mucinous tumor growth.
Dilly AK; Song X; Zeh HJ; Guo ZS; Lee YJ; Bartlett DL; Choudry HA
Transl Res; 2015 Oct; 166(4):344-54. PubMed ID: 25890193
[TBL] [Abstract][Full Text] [Related]
3. Targeting hypoxia-mediated mucin 2 production as a therapeutic strategy for mucinous tumors.
Dilly AK; Lee YJ; Zeh HJ; Guo ZS; Bartlett DL; Choudry HA
Transl Res; 2016 Mar; 169():19-30.e1. PubMed ID: 26589109
[TBL] [Abstract][Full Text] [Related]
4. MUC2 is a molecular marker for pseudomyxoma peritonei.
O'Connell JT; Hacker CM; Barsky SH
Mod Pathol; 2002 Sep; 15(9):958-72. PubMed ID: 12218214
[TBL] [Abstract][Full Text] [Related]
5. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells.
O'Connell JT; Tomlinson JS; Roberts AA; McGonigle KF; Barsky SH
Am J Pathol; 2002 Aug; 161(2):551-64. PubMed ID: 12163380
[TBL] [Abstract][Full Text] [Related]
6. Mucinous Balls Tangled With Mesothelial Cells and MUC2-Positive Cancer Cells in the Ascites of Pseudomyxoma Peritonei.
Akashi S; Kuwabara H; Yasuda E; Akutagawa H; Takeshita A; Kurisu Y; Egashira Y; Hirose Y; Yuki M; Tsuda Y; Hayashi M
Diagn Cytopathol; 2016 Jul; 44(7):628-31. PubMed ID: 27079739
[TBL] [Abstract][Full Text] [Related]
7. Targeting G-protein coupled receptor-related signaling pathway in a murine xenograft model of appendiceal pseudomyxoma peritonei.
Dilly AK; Honick BD; Lee YJ; Guo ZS; Zeh HJ; Bartlett DL; Choudry HA
Oncotarget; 2017 Dec; 8(63):106888-106900. PubMed ID: 29290997
[TBL] [Abstract][Full Text] [Related]
8. Patient-derived xenograft mouse models of pseudomyxoma peritonei recapitulate the human inflammatory tumor microenvironment.
Kuracha MR; Thomas P; Loggie BW; Govindarajan V
Cancer Med; 2016 Apr; 5(4):711-9. PubMed ID: 26833741
[TBL] [Abstract][Full Text] [Related]
9. Slippery Nanoparticles as a Diffusion Platform for Mucin Producing Gastrointestinal Tumors.
Khalili M; Zhou H; Thadi A; Daniels L; Fan Z; Morano WF; Ang J; Goldstein E; Polyak B; Mapow BC; Cheng H; Bowne WB
Ann Surg Oncol; 2020 Jan; 27(1):76-84. PubMed ID: 31187366
[TBL] [Abstract][Full Text] [Related]
10. Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis.
Semino-Mora C; Liu H; McAvoy T; Nieroda C; Studeman K; Sardi A; Dubois A
Ann Surg Oncol; 2008 May; 15(5):1414-23. PubMed ID: 18299935
[TBL] [Abstract][Full Text] [Related]
11. In vivo model of pseudomyxoma peritonei for novel candidate drug discovery.
Chua TC; Akther J; Yao P; Morris DL
Anticancer Res; 2009 Oct; 29(10):4051-5. PubMed ID: 19846950
[TBL] [Abstract][Full Text] [Related]
12. A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process.
Carr NJ; Cecil TD; Mohamed F; Sobin LH; Sugarbaker PH; González-Moreno S; Taflampas P; Chapman S; Moran BJ;
Am J Surg Pathol; 2016 Jan; 40(1):14-26. PubMed ID: 26492181
[TBL] [Abstract][Full Text] [Related]
13. Ovarian mucinous tumour arising in mature cystic teratoma and associated with pseudomyxoma peritonei: report of two cases and comparison with ovarian involvement by low-grade appendiceal mucinous tumour.
Stewart CJ; Tsukamoto T; Cooke B; Leung YC; Hammond IG
Pathology; 2006 Dec; 38(6):534-8. PubMed ID: 17393980
[TBL] [Abstract][Full Text] [Related]
14. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases.
Nonaka D; Kusamura S; Baratti D; Casali P; Younan R; Deraco M
Histopathology; 2006 Oct; 49(4):381-7. PubMed ID: 16978201
[TBL] [Abstract][Full Text] [Related]
15. A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei.
Bibi R; Pranesh N; Saunders MP; Wilson MS; O'dwyer ST; Stern PL; Renehan AG
Br J Cancer; 2006 Nov; 95(9):1258-64. PubMed ID: 17031402
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Arising from Urachus.
Liu Y; Ishibashi H; Hirano M; Takeshita K; Mizumoto A; Ichinose M; Nishino E; Kashu I; Yamamoto Y; Sugarbaker PH; Yonemura Y
Ann Surg Oncol; 2015 Aug; 22(8):2799-805. PubMed ID: 25572681
[TBL] [Abstract][Full Text] [Related]
17. Macroscopic and microscopic characteristics of low grade appendiceal mucinous neoplasms (LAMN) on appendectomy specimens and correlations with pseudomyxoma peritonei development risk.
Hegg KS; Mack LA; Bouchard-Fortier A; Temple WJ; Gui X
Ann Diagn Pathol; 2020 Oct; 48():151606. PubMed ID: 32889392
[TBL] [Abstract][Full Text] [Related]
18. MUC2, MUC5AC and MUC5B in the mucus of a patient with pseudomyxoma peritonei: biochemical and immunohistochemical study.
Mall AS; Chirwa N; Govender D; Lotz Z; Tyler M; Rodrigues J; Kahn D; Goldberg P
Pathol Int; 2007 Aug; 57(8):537-47. PubMed ID: 17610480
[TBL] [Abstract][Full Text] [Related]
19. Leptin, MUC2 and mTOR in appendiceal mucinous neoplasms.
Chang MS; Byeon SJ; Yoon SO; Kim BH; Lee HS; Kang GH; Kim WH; Park KJ
Pathobiology; 2012; 79(1):45-53. PubMed ID: 22236547
[TBL] [Abstract][Full Text] [Related]
20. Experimental models and questions in basic science research for pseudomyxoma peritonei.
Lambert LA; Lambert DH; Mansfield P
Recent Results Cancer Res; 2007; 169():105-14. PubMed ID: 17506254
[No Abstract] [Full Text] [Related]
[Next] [New Search]
